Cargando…
A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases
Skeletal tumour burden is a biomarker of prognosis and survival in cancer patients. This study proposes a novel method based on the linear quadratic model to predict the reduction in metastatic tumour burden as a function of the absorbed doses delivered from molecular radiotherapy treatments. The ra...
Autores principales: | Denis-Bacelar, Ana M, Chittenden, Sarah J, Murray, Iain, Divoli, Antigoni, Ralph McCready, V, Dearnaley, David P, O’Sullivan, Joe M, Johnson, Bernadette, Flux, Glenn D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOP Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953197/ https://www.ncbi.nlm.nih.gov/pubmed/28291739 http://dx.doi.org/10.1088/1361-6560/aa5e6f |
Ejemplares similares
-
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy
por: Denis-Bacelar, Ana M, et al.
Publicado: (2018) -
Phase I/II trials of (186)Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival
por: Denis-Bacelar, Ana M., et al.
Publicado: (2016) -
Opportunities for research in molecular radiotherapy
por: Flux, Glenn D, et al.
Publicado: (2017) -
Radiobiology of stereotactic radiotherapy
por: Mangoni, Monica, et al.
Publicado: (2022) -
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone
por: O'Sullivan, J M, et al.
Publicado: (2002)